Our publications

The main goal of this report is to allow health administration and clinical decision-makers in Montréal be more aware of health services utilisation by diabetics in their territories. The report on diabetes is part of the “Monitorage interprétatif” project conducted by the Équipe Santé des populations et services de santé (ESPSS), a joint team of the Montréal Public Health Department and the Institut national de santé publique du Québec.

The live attenuated influenza virus vaccine (LAIV), Flumist®, administered by intranasal spray, is approved for people aged 2-59 years. The National Advisory Committee on Immunization (NACI) recommended in its statement for the 2011-2012 season that, given its efficacy and immunogenicity, LAIV should be used preferentially for healthy children and adolescents aged 2 to 17 years.

How can we perceive and address ethical challenges in public health practice and policy? One way is by using ethical concepts to shed light on everyday practice. One does not have to be a specialist in ethics to do so. This document is part of a series of papers intended to introduce practitioners to some concepts, values, principles, theories and approaches that are important to public health ethics.

From April 1, 2015, to March 31, 2016, 89 healthcare facilities took part in the surveillance of healthcare-associated vancomycin-resistant enterococci (VRE) infections, for a combined total of 4,833,086 patient days (Table 1). In total, 78 VRE infections were reported among patients who contracted strain during a current or previous hospital stay in the reporting facility (categories 1a and 1b). The incidence rate of healthcare-associated VRE infection (cat. 1a and 1b) was 0.16 per 10…

From April 1, 2013, to March 31, 2014, 89 healthcare facilities took part in the surveillance of healthcare-associated vancomycin-resistant enterococci (VRE) infections, for a combined total of 4,948,058 patient days (Table 1). In total, 92 VRE infections were reported among patients who contracted strain during a current or previous hospital stay in the reporting facility (categories 1a + 1b). The incidence rate of healthcare-associated VRE infections (cat. 1a + 1b) was 0.19 / 10…

From April 1, 2014, to March 31, 2015, 89 healthcare facilities took part in the surveillance of healthcare-associated vancomycin-resistant enterococci (VRE) infections, for a combined total of 4,839,578 patient days (Table 1). In total, 87 VRE infections were reported among patients who contracted strain during a current or previous hospital stay in the reporting facility (categories 1a + 1b). The incidence rate of healthcare-associated VRE infections (cat. 1a + 1b) was 0.18 / 10…

From April 1, 2012, to March 31, 2013, 89 healthcare facilities took part in the surveillance of healthcare-associated vancomycin-resistant enterococci (HA-VRE) infections, for a combined total of 5,017,791 patient days. In total, 41 cases of VRE infection were reported among patients who contracted the strain during a current or previous hospital stay in the reporting facility (categories 1a + 1b). The incidence rate of HA-VRE infection (cat. 1a + 1b) was 0.08/10,000…

From April 1^st, 2016 to March 31^st, 2017, 89 healthcare facilities took part in the surveillance of vancomycin-resistant enterococci (VRE) infections, for a combined total of 4,827,659 patient days (Table 1). These facilities reported 44 healthcare-associated VRE (HA-VRE) infections, either acquired during a current or previous hospitalization (categories 1a and 1b). The HA-VRE infection rate was 0.09 per 10,000 patient days. This incidence rate was down from 2015…

From April 1st, 2014, to March 31st, 2015, 45 hemodialysis units took part in the surveillance of vascular access–related bloodstream infections (VARBSIs) in hemodialysis (HD) patients, for a combined total of 55,640 patient-periods (Table 1). Participating units reported 156 VARBSIs in 142 patients. The proportion of patient-periods involving a fistula accounted for 43.4%. The VARBSI incidence rate was 0.09 cases per 100 patient-periods…

From April 1^st, 2016, to March 31^st, 2017, 48 hemodialysis units took part in the surveillance of vascular access–related bloodstream infections (VARBSIs) in hemodialysis (HD) patients, for a combined total of 57,570 patient-periods (Table 1). Participating units reported 127 VARBSIs in 120 patients. Patient-periods involving a fistula account for 40.7% of patient-periods. The VARBSI incidence rate is 0.06 cases per 100…